MA48971B1 - Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant - Google Patents

Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant

Info

Publication number
MA48971B1
MA48971B1 MA48971A MA48971A MA48971B1 MA 48971 B1 MA48971 B1 MA 48971B1 MA 48971 A MA48971 A MA 48971A MA 48971 A MA48971 A MA 48971A MA 48971 B1 MA48971 B1 MA 48971B1
Authority
MA
Morocco
Prior art keywords
tetrahydrate
ligand
pharmaceutical compositions
preparation process
preparation
Prior art date
Application number
MA48971A
Other languages
English (en)
Other versions
MA48971A (fr
Inventor
Jean-Charles Schwartz
Jeanne-Marie Lecomte
Marc Capet
Original Assignee
Bioprojet Soc Civ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioprojet Soc Civ filed Critical Bioprojet Soc Civ
Publication of MA48971A publication Critical patent/MA48971A/fr
Publication of MA48971B1 publication Critical patent/MA48971B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)

Abstract

La présente invention concerne la forme tétrahydrate du composé : (3s)-4-{4-[3-(3-méthylpipéridin-1-yl)propoxy]phényl}pyridine 1-oxide, dichlorhydrate, son procédé de préparation et ses utilisations thérapeutiques.
MA48971A 2017-03-21 2018-03-20 Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant MA48971B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17305310.9A EP3378858A1 (fr) 2017-03-21 2017-03-21 Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant
PCT/EP2018/056999 WO2018172344A1 (fr) 2017-03-21 2018-03-20 Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques les comprenant

Publications (2)

Publication Number Publication Date
MA48971A MA48971A (fr) 2020-02-05
MA48971B1 true MA48971B1 (fr) 2021-03-31

Family

ID=58488932

Family Applications (1)

Application Number Title Priority Date Filing Date
MA48971A MA48971B1 (fr) 2017-03-21 2018-03-20 Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant

Country Status (21)

Country Link
US (1) US11078183B2 (fr)
EP (2) EP3378858A1 (fr)
JP (1) JP7235671B2 (fr)
KR (1) KR102608265B1 (fr)
CN (1) CN110891948B (fr)
AU (1) AU2018238260B2 (fr)
BR (1) BR112019019643A2 (fr)
CA (1) CA3056490A1 (fr)
CY (1) CY1124114T1 (fr)
DK (1) DK3601252T3 (fr)
ES (1) ES2868024T3 (fr)
HR (1) HRP20210312T1 (fr)
HU (1) HUE053710T2 (fr)
IL (1) IL269360B2 (fr)
LT (1) LT3601252T (fr)
MA (1) MA48971B1 (fr)
PL (1) PL3601252T3 (fr)
PT (1) PT3601252T (fr)
RS (1) RS61511B1 (fr)
WO (1) WO2018172344A1 (fr)
ZA (1) ZA201906202B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3378477A1 (fr) * 2017-03-21 2018-09-26 BIOPROJET Pharma Nouvelles utilisations thérapeutiques de ligands h3
PT3598975T (pt) 2018-07-27 2020-12-21 Bioprojet Soc Civ Novas combinações de um antagonista h3 e um inibidor da re-assimilação da noradrenalina, e suas utilizações terapêuticas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003095447A1 (fr) * 2002-05-14 2003-11-20 Xenova Limited Procede de preparation d'un hydrate de derive d'acide anthranilique
US8158652B2 (en) * 2004-12-01 2012-04-17 Msd K.K. Substituted pyridone derivative
EP1717235A3 (fr) * 2005-04-29 2007-02-28 Bioprojet Phenoxypropylpiperidines and -pyrrolidines et leur utilisation comme ligands du récepteur histaminique H3
TWI555741B (zh) * 2011-12-08 2016-11-01 大正製藥股份有限公司 Phenylpyrrole derivatives
EP2799436A4 (fr) * 2011-12-27 2015-07-01 Taisho Pharmaceutical Co Ltd Dérivé de phényltriazole
EP3378477A1 (fr) * 2017-03-21 2018-09-26 BIOPROJET Pharma Nouvelles utilisations thérapeutiques de ligands h3
PT3598975T (pt) * 2018-07-27 2020-12-21 Bioprojet Soc Civ Novas combinações de um antagonista h3 e um inibidor da re-assimilação da noradrenalina, e suas utilizações terapêuticas

Also Published As

Publication number Publication date
AU2018238260B2 (en) 2021-07-22
HUE053710T2 (hu) 2021-07-28
IL269360B (en) 2022-10-01
CN110891948B (zh) 2022-11-11
KR20200008995A (ko) 2020-01-29
EP3378858A1 (fr) 2018-09-26
US20200024256A1 (en) 2020-01-23
CA3056490A1 (fr) 2018-09-27
MA48971A (fr) 2020-02-05
CY1124114T1 (el) 2022-05-27
JP2020511507A (ja) 2020-04-16
US11078183B2 (en) 2021-08-03
PL3601252T3 (pl) 2021-08-02
RU2019129432A3 (fr) 2021-07-01
IL269360A (en) 2019-11-28
RU2019129432A (ru) 2021-03-18
WO2018172344A1 (fr) 2018-09-27
LT3601252T (lt) 2021-04-26
IL269360B2 (en) 2023-02-01
HRP20210312T1 (hr) 2021-04-02
EP3601252A1 (fr) 2020-02-05
DK3601252T3 (da) 2021-03-08
KR102608265B1 (ko) 2023-11-30
EP3601252B1 (fr) 2021-02-17
RS61511B1 (sr) 2021-03-31
PT3601252T (pt) 2021-03-31
AU2018238260A1 (en) 2019-10-10
CN110891948A (zh) 2020-03-17
ES2868024T3 (es) 2021-10-21
BR112019019643A2 (pt) 2020-04-14
JP7235671B2 (ja) 2023-03-08
ZA201906202B (en) 2020-10-28

Similar Documents

Publication Publication Date Title
PH12018500554A1 (en) Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
PH12018500610A1 (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
GEP20207117B (en) Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
MX2017016376A (es) Derivado de piperidina y metodo de preparacion y uso farmaceutico del mismo.
EA201892838A1 (ru) Новые пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
MX2018012085A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
PH12018500626A1 (en) Isoindolinone inhibitors of the mdm2-p53 interaction having anticancer activity
PH12016501962B1 (en) Macrocyclic pyridine derivatives
PH12019550111A1 (en) Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitors
BR112014007163A2 (pt) composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
EA200970349A1 (ru) Ингибиторы металлопротеазы гетероциклического происхождения
MX2017008112A (es) Procedimientos para preparar compuestos de tipo oxatiazina.
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MY185516A (en) Compositions and methods for treating schizophrenia
EA201070691A1 (ru) Амидные соединения в качестве активаторов противовирусных препаратов
MX2019013979A (es) Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol.
MA48971B1 (fr) Tétrahydrate de ligand h3, son procédé de préparation et compositions pharmaceutiques le comprenant
BR112017025023A2 (pt) Compostos heterocíclicos de carbamato de 3,3- difluoropiperidina como antagonistas do receptor nmda nr2b
MX2018001979A (es) (s,e) -3- (6-aminopiridin-3-il) -n- ( (5- (4- (3-fluoruro-3 metilpirrolidin-1-carbonil) fenil) -7- (4 fluorofenil) benzofuran-2-il)metil)acrilamida para el tratamiento del cancer.
PH12017501130A1 (en) Indenyl compounds, pharmaceutical compositions, and medical uses thereof
MX2019012505A (es) Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
MX2019012454A (es) Compuesto solido cristalino novedoso de clorhidrato de 3-fenil-4-propil-1-(piridin-2-il)-1h-pirazol-5-ol.